SCIENTIFIC EVIDENCE

Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8+ T-cell activation

BMC medicine

Tang S, Han M, Wang P, Lu F, Zhang Y, Li Z, Zhou S, Zhang Y, Wang Z, Zhao J, Luo Y, Tian Z, Feng M, Zhu G, Wu L, Liang D.

Publication Overview

Key findings, Countstar context, and access to the original paper.

2026

Cancer Research

Immunology

Key Finding

This study examines cell-based delivery of IL-2 in cancer models.

Countstar Connection

The researchers counted cells with the Countstar Rigel S2.

Stay Connected to

Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.

Meet us online